Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
stocks
The largest share trading on the ASX remains materially overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.40 | 38.00 | -0.42% |
| CAC 40 | 8,239.54 | 83.31 | 1.02% |
| DAX 40 | 24,364.28 | 276.22 | 1.15% |
| Dow JONES (US) | 47,927.96 | 559.33 | 1.18% |
| FTSE 100 | 9,890.20 | 9.40 | -0.09% |
| HKSE | 26,922.73 | 226.32 | 0.85% |
| NASDAQ | 23,468.30 | 58.87 | -0.25% |
| Nikkei 225 | 51,063.31 | 220.38 | 0.43% |
| NZX 50 Index | 13,671.73 | 67.18 | 0.49% |
| S&P 500 | 6,846.61 | 14.18 | 0.21% |
| S&P/ASX 200 | 8,799.50 | 36.50 | -0.41% |
| SSE Composite Index | 4,000.14 | 2.62 | -0.07% |